Member Info for Timster

So it's just posters presenting this data is it?

This market is only interested in finance. If the company was valued on science it'd be billions.

We wait for partners, licensing or take over.

LDA you of all people know not to talk light of tucandooms issues

Anyone there with a Daiichi Sankyo rucksack

Half an hour in to science day, must be some knowing nods and winks from CC to report on???

Oh dear tucandoom, rough night?

Doesn't mention commercial announcements here

"The Avacta Science Day event for investors will take place in Central London on May 6, 2026 commencing at 10.30 AM, at the Royal Society of Chemistry, Burlington House, Piccadilly, London W1J 0BA. Avacta team members will share presentations on the company's scientific achievements and our aspirations,"

MASSIVE deals mist be after hours.

Big farmer can't ignore Avacta, shots fired.

Maybe Alan is a guest speaker to confirm that the Pre|CISION pdc is actually an ADC.

Like when he forgot to tell us the affimer lft had antibodies in it 👍

Tried your best Doggy, wouldn't want to be out before science day though, madness!!

NY online?

Let's just say it might go up or down or stay the same.

Convert that sentence into a huge boring essay to save wynbore the trouble

Science day won't include any new financial info.

So chances are no effect on SP.

Massive not massage

My wellness routine revealed live on LSE

Massage deal announced at 7, new owners and science shown off on the day.

Market doesn't care about science, it cares about finances.

Strangely Viking they didn't just chuck this out, trials have been ongoing for a while:

The clinical development of the subcutaneous formulation of Keytruda (Keytruda QL) progressed through several trial phases starting in 2021:

Trial Start Dates

Phase 1 (Bioavailability Study): The initial study evaluating the subcutaneous delivery of pembrolizumab (NCT05017012) officially began on 21 September 2021.

Phase 3 (Pivotal Trial): The MK-3475A-D77 study (NCT05722015), which supported the final FDA approval, began on 14 February 2023.

ClinicalTrials.gov

+3

Trial Timeline Overview

February 2023: Phase 3 trial initiation for first-line treatment of metastatic non-small cell lung cancer (NSCLC).

July 2024: Primary completion of the Phase 3 trial, providing the key data on pharmacokinetics and safety.

November 2024: Merck announced that the Phase 3 trial met its primary endpoints.

September 2025: Official FDA approval for adult and paediatric solid tumor

Is it us?

He said that at a science day too, no coincidence there's another science day coming.